> For the complete documentation index, see [llms.txt](https://www.thiamine.wiki/llms.txt). Markdown versions of documentation pages are available by appending `.md` to page URLs; this page is available as [Markdown](https://www.thiamine.wiki/biochemistry/novel-derivatives.md).

# novel derivatives

{% hint style="info" %}
**Section:** Complete Biochemistry → Thiamine Derivatives\
**Reading level:** Technical, with a plain-language summary\
**Last reviewed:** October 2026 · **Evidence status:** Mostly preclinical or early-stage (labelled for each topic)
{% endhint %}

## Summary

Research on thiamine derivatives is moving in several directions:

* **Revisiting older compounds**, such as dibenzoylthiamine and cycotiamine, which were made in Japan decades ago but little studied.
* **Searching for the active metabolites** that may explain effects of thioester derivatives not accounted for by thiamine delivery.
* **Using thiamine analogues as tools and drug leads**, from cancer and antimicrobial research to agricultural chemistry.
* **Developing new delivery strategies**, including brain-targeted designs.

Most of this work is **preclinical**. The main clinical development at present is the ongoing benfotiamine trial in early Alzheimer's disease.

## Revived and lesser-known thiamine prodrugs

| Compound                             | Chemistry                                                                                                                       | Status                                                                                                                                    |
| ------------------------------------ | ------------------------------------------------------------------------------------------------------------------------------- | ----------------------------------------------------------------------------------------------------------------------------------------- |
| **Dibenzoylthiamine (DBT)**          | O,S-dibenzoyl thioester                                                                                                         | Active preclinical research; no published human trials (see [Dibenzoylthiamine](broken://pages/61b9d87ea2cbca6001a269c28ff14a79807693f2)) |
| **Cycotiamine** (cyclocarbothiamine) | Open-ring thiamine in which the sulfur and the side-chain oxygen are joined in a cyclic thiocarbonate (1,3-oxathian-2-one) ring | Developed in Japan in the 1960s; little modern published research found                                                                   |
| **Cetotiamine**                      | O,S-diethoxycarbonyl thiamine                                                                                                   | Older Japanese derivative; limited modern data                                                                                            |
| **Bisbentiamine**                    | O-benzoyl thiamine disulfide dimer                                                                                              | Older Japanese derivative; limited modern data                                                                                            |
| **Allithiamine and prosultiamine**   | Allyl and propyl disulfides                                                                                                     | Allithiamine is the natural prototype; prosultiamine studied in HTLV-1-associated myelopathy (small open-label trial)                     |

### Thioesters as a research focus

A 2023 review proposed synthetic thiamine thioesters, notably **benfotiamine** and **DBT**, as candidate tools for slowing neurodegenerative disease. Its key points were:

* benfotiamine has shown benefits in rodent models and some human studies;
* DBT appears **more potent than benfotiamine** in vitro, particularly as an anti-inflammatory agent;
* antioxidant and anti-inflammatory effects of thioesters appear partly **independent of TPP's coenzyme role**;
* effects may be mediated by **as-yet-unidentified open-thiazole-ring metabolites**, and identifying them is a priority.

## Thiamine antagonists and analogues

Thiamine analogues that block thiamine uptake, activation or function are valuable research tools. Some are also being explored as drugs.

| Compound                                              | Mechanism                                                                                                    | Uses                                                                                                 |
| ----------------------------------------------------- | ------------------------------------------------------------------------------------------------------------ | ---------------------------------------------------------------------------------------------------- |
| **Oxythiamine**                                       | Phosphorylated by TPK1 to oxythiamine pyrophosphate, which inhibits transketolase and pyruvate dehydrogenase | Research on cancer metabolism (inhibiting ribose synthesis); antimicrobial and antimalarial research |
| **Pyrithiamine**                                      | Inhibits TPK1; its pyrophosphate binds TPP riboswitches in microbes                                          | Inducing thiamine deficiency in rodent models of Wernicke encephalopathy; antimicrobial research     |
| **Amprolium**                                         | Competitive inhibitor of thiamine transport                                                                  | Veterinary anticoccidial drug; research tool                                                         |
| **3-Deazathiamine diphosphate and related analogues** | Neutral mimics of the TPP ylide that bind TPP enzymes very tightly                                           | Mechanistic enzymology; leads for selective enzyme inhibitors                                        |
| **Triazole-based and other synthetic TPP analogues**  | Replace the thiazolium and/or diphosphate with stable mimics                                                 | Inhibitors of specific TPP-dependent enzymes (e.g. pyruvate dehydrogenase, microbial enzymes)        |

## Targeting TPP-dependent processes in microbes and plants

| Target                                    | Rationale                                                             | Stage                                                     |
| ----------------------------------------- | --------------------------------------------------------------------- | --------------------------------------------------------- |
| **DXP synthase** (MEP isoprenoid pathway) | Essential in many bacteria and in malaria parasites; absent in humans | Drug discovery research                                   |
| **TPP riboswitches**                      | Regulate thiamine genes in bacteria and fungi; absent in animals      | Antimicrobial research (pyrithiamine as proof of concept) |
| **Acetohydroxyacid synthase**             | Branched-chain amino acid synthesis in plants and microbes            | Established herbicide target; antimicrobial research      |
| **Pyruvate:ferredoxin oxidoreductase**    | Central to anaerobic metabolism in some parasites and bacteria        | Target of existing antiparasitic drugs                    |

## Delivery strategies

| Strategy                                                      | Idea                                                                         | Evidence                                                  |
| ------------------------------------------------------------- | ---------------------------------------------------------------------------- | --------------------------------------------------------- |
| **Lipophilic prodrugs** (existing disulfides and thioesters)  | Mask the thiazolium charge to bypass transporters                            | **Established** for blood levels; variable for brain      |
| **Brain-targeted prodrugs**                                   | Exploit blood–brain barrier transporters or lipophilicity to raise brain TPP | **Early research**                                        |
| **Liposomal, transdermal and other novel supplement formats** | Claimed to improve absorption                                                | **Little or no peer-reviewed pharmacokinetic data** found |
| **Parenteral routes** (IV, IM)                                | Bypass the gut                                                               | **Established** clinically for deficiency                 |

{% hint style="warning" %}
**Evidence note:** novel delivery formats are sometimes marketed with absorption claims that have not been tested in published pharmacokinetic studies. Claims of superior bioavailability should be supported by human data comparing blood (and ideally tissue) thiamine levels with standard forms at equal thiamine content.
{% endhint %}

## Clinical pipeline

| Trial or programme          | Compound                           | Condition                 | Status                                                        |
| --------------------------- | ---------------------------------- | ------------------------- | ------------------------------------------------------------- |
| **BenfoTeam** (NCT06223360) | Benfotiamine (600 or 1,200 mg/day) | Early Alzheimer's disease | Phase 2a/2b; started 2024; estimated completion December 2027 |
| Other derivatives           | DBT, cycotiamine and others        | —                         | No registered late-stage trials identified                    |

## What future research needs to show

For any thiamine derivative to move from promising to proven, the following evidence is needed:

{% stepper %}
{% step %}

### Human pharmacokinetics

Blood and, where relevant, cerebrospinal fluid or brain levels (for example, by imaging or spectroscopy), compared with thiamine salts and other derivatives at equal thiamine content.
{% endstep %}

{% step %}

### Identification of active metabolites

Particularly for thioesters.
{% endstep %}

{% step %}

### Independent replication

Replication of preclinical findings in more than one laboratory and more than one model.
{% endstep %}

{% step %}

### Adequately powered randomized controlled trials

Trials with clinically meaningful outcomes, ideally including people with documented low thiamine status.
{% endstep %}

{% step %}

### Head-to-head comparisons

Comparisons between derivatives and with high-dose thiamine salts.
{% endstep %}

{% step %}

### Long-term safety data

Especially for compounds with little clinical history.
{% endstep %}
{% endstepper %}

## Evidence quality

| Claim type                                                        | Strength                                    |
| ----------------------------------------------------------------- | ------------------------------------------- |
| Antagonist mechanisms (oxythiamine, pyrithiamine, amprolium)      | **Strong**                                  |
| Thioesters having TPP-independent effects                         | **Preclinical**; active metabolites unknown |
| Revived derivatives (DBT, cycotiamine) providing clinical benefit | **No human evidence**                       |
| Novel supplement delivery formats                                 | **Largely untested**                        |

## Open questions

* What are the active metabolites of thiamine thioesters, and could they be developed directly as drugs?
* Can a derivative be designed that reliably raises brain TPP in humans?
* Could selective inhibitors of microbial TPP enzymes become useful antibiotics or antimalarials?

## Related pages

* [Thiamine Derivatives (Overview)](broken://pages/44390ee2e231e4f690942c9b807cab9f6eb7272d)
* [Dibenzoylthiamine (DBT)](broken://pages/61b9d87ea2cbca6001a269c28ff14a79807693f2)
* [Benfotiamine](broken://pages/75effe2f75d8702a4645b72eb76b7a3b69392e6d)
* [TPP-Dependent Enzymes](broken://pages/48b61d9218e12eeb5f0e1876c67ae5de17b143ff)
* [Thiamine Structure](broken://pages/e97e22d3de70d018c7c19aa407e5feb03d96c2a0)

## References

1. \[Authors to be confirmed]. Synthetic thioesters of thiamine: promising tools for slowing progression of neurodegenerative diseases. *International Journal of Molecular Sciences*. 2023;24(14):11296.
2. Sambon M, Wins P, Bettendorff L. Neuroprotective effects of thiamine and precursors with higher bioavailability: focus on benfotiamine and dibenzoylthiamine. *International Journal of Molecular Sciences*. 2021;22(11):5418.
3. Murakami M, et al. (Yamanouchi Seiyaku). Cycotiamine (cyclocarbothiamine). US Patent 3,324,124; 1967.
4. Nakamura T, et al. Efficacy of prosultiamine treatment in patients with human T lymphotropic virus type I-associated myelopathy/tropical spastic paraparesis: results from an open-label clinical trial. *BMC Medicine*. 2013;11:182.
5. Boros LG, et al. Oxythiamine and dehydroepiandrosterone inhibit the nonoxidative synthesis of ribose and tumor cell proliferation. *Cancer Research*. 1997;57(19):4242–4248.
6. Sudarsan N, et al. Thiamine pyrophosphate riboswitches are targets for the antimicrobial compound pyrithiamine. *Chemistry & Biology*. 2005;12(12):1325–1335.
7. Jordan F. Current mechanistic understanding of thiamin diphosphate-dependent enzymatic reactions. *Natural Product Reports*. 2003;20(2):184–201.
8. ClinicalTrials.gov. A trial to evaluate the safety and efficacy of benfotiamine in patients with early Alzheimer's disease (BenfoTeam). NCT06223360.

{% hint style="info" %}
**Editorial note:** This page describes mechanisms and published evidence. It is not medical advice and does not recommend doses. Suggest corrections or new sources via the feedback link.
{% endhint %}
